Developing as a promising development in the fight against obesity, the drug is capturing considerable attention . It combines the action of two established GLP-1 binding agonists, semaglutide , with an unique glucose-dependent peptide component. Initial clinical findings have demonstrated impressive body loss in patients with excessive weight,… Read More